17:12 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Sanofi drops two clinical assets; reports rebounding Dupixent sales

Sanofi (Euronext:SAN; NYSE:SNY) disclosed in its 2Q18 earnings that it ended development of antibody-drug conjugate (ADC) SAR566658 to treat triple-negative breast cancer (TNBC), as well as a recombinant subunit vaccine to treat tuberculosis. A Sanofi...
07:00 , Jun 1, 2009 |  BC Week In Review  |  Clinical News

Zeltia preclinical data

In a rabbit model of hypertension, SYL040003 prevented intraocular pressure increase and ocular hypertension induced by oral gravage. Data on the topically administered siRNA directed against carbonic anhydrase IV (CAIV) were presented at the Association...
08:00 , Jan 7, 2008 |  BioCentury  |  Finance

New products to watch

New products to watch...
07:00 , Jul 16, 2007 |  BC Week In Review  |  Company News

Drug Royalty, University of Michigan deal

Drug Royalty acquired the university's future royalties on the sales of FluMist intranasal influenza vaccine for up to $35 million based on undisclosed conditions. In January, FDA approved a refrigerator-stable formulation of FluMist (formerly CAIV-T),...
01:18 , Jul 11, 2007 |  BC Extra  |  Company News

Drug Royalty acquires FluMist royalties

Drug Royalty (Toronto, Ontario) acquired the University of Michigan's future royalties on sales of FluMist intranasal influenza vaccine for up to $35 million. FluMist posted $36 million in sales last year. In January, FDA approved...
07:00 , May 21, 2007 |  BC Week In Review  |  Clinical News

CAIV-T vaccine regulatory update

FDA's Vaccines and Related Biological Products Advisory Committee voted in favor of expanding the label of CAIV-T intranasal influenza vaccine to include children 12-59 months of age without history of wheeze. The committee voted 15-0...
07:00 , May 21, 2007 |  BioCentury  |  Finance

Ebb & Flow

Novartis...
01:16 , May 17, 2007 |  BC Extra  |  Company News

FDA panel backs expanded label for CAIV-T

MedImmune (MEDI) said on Wednesday that FDA's Vaccines and Related Biological Products Advisory Committee voted in favor of expanding the label of CAIV-T intranasal influenza vaccine to include children 12-59 months of age without history...
01:48 , May 15, 2007 |  BC Extra  |  Company News

FDA releases CAIV-T documents

FDA will ask the Vaccines and Related Biological Products Advisory Committee on Wednesday whether the benefit/risk profile of CAIV-T intranasal influenza vaccine from MedImmune (MEDI) warrants approval in children 12-23 months of age. Data from...
07:00 , Apr 30, 2007 |  BC Week In Review  |  Company News

MedImmune Inc., AstraZeneca deal

AZN will acquire MEDI for $15.6 billion based on $58 for each of MEDI’s 283.9 diluted shares, less about $900 million in proceeds from 30.1 million exercised options. The deal value is about 10 times...